About RareTrial
The rare disease
intelligence layer
the internet was missing.
300 million people live with a rare disease worldwide. Most spend years searching scattered databases, impenetrable government portals, and academic registries just to understand what exists for their condition. RareTrial changes that.
Our mission
"A rare disease diagnosis should not mean years of searching. Every patient deserves to know what exists: the trials, the drugs in development, the people who understand what they are going through."
RareTrial was built on one belief: that the information exists, scattered across government databases, research registries, clinical trial portals, and pharmaceutical pipelines, but the work of connecting it all, translating it into plain language, and presenting it in a way that a patient or carer can actually use, had never been done at scale. Until now.
The problem we solve
Finding information about a rare disease
should not be this hard.
Scattered information
Clinical trials live on one platform. Drug pipelines are buried in research papers. Patient organisations are found by word of mouth. No one had assembled it all in one place.
Inaccessible language
Most databases were built for researchers and regulators. A patient searching for hope should not need a medical degree to understand what they are reading.
Invisible pipeline
Drugs that could change a patient's life are in development right now. That information is publicly available, but hidden in databases that require specialist knowledge to navigate.
What RareTrial contains
Four layers of intelligence,
one seamless experience.
10,899-Disease Library
Every rare disease page covers clinical features, causes, how it presents, and what is known about it, drawn from Orphanet data (CC BY 4.0) and presented in plain, readable language. One of the largest rare disease directories ever built.
Clinical Trial Finder
Pulling from ClinicalTrials.gov, the world's largest clinical trial registry, we surface active studies for each disease in plain language. Search by disease, phase, location, or recruitment status without needing to decode government database syntax.
Drug Pipeline Intelligence
Sourced from Open Targets Platform (CC BY 4.0), the gold standard in drug-disease evidence, we show every drug in development for each rare disease: approved treatments, Phase 3 candidates, early-phase research. 12,000+ drugs tracked across 1,000+ rare diseases.
Patient Organisation Directory
For hundreds of diseases, we connect patients directly to charities, advocacy groups, patient registries, and foundations. Because knowing you are not alone is as important as any clinical data. Universal fallback links to NORD, GARD, and Orphanet for every disease.
Who it is for
Built for the patient first.
Useful to everyone who serves them.
Patients & Families
You or someone you love has just received a rare diagnosis. RareTrial is where you come first. Find active trials, understand what treatments exist, and connect with the community that knows your disease from the inside.
- Plain-language disease information
- Active trials searchable in seconds
- Drug pipeline: hope on the horizon
- Patient organisations by disease
Healthcare Professionals
A rare diagnosis in clinic is a research task most clinicians did not train for. RareTrial gives you the landscape in minutes: what is approved, what is in trials, what your patient might ask about next.
- Rapid disease briefing before a consult
- Trial eligibility overview at a glance
- Drug pipeline by phase and mechanism
- Download-ready patient-facing resources
Researchers & Industry
The rare disease space moves fast and coverage is uneven. RareTrial provides a free landscape view across 10,899 diseases: trial gaps, pipeline density, patient organisation maturity. A starting point for strategy, not a replacement for it.
- Competitive pipeline visibility
- Patient community mapping
- White-label and industry partnerships available
- Trial recruitment patient outreach
Why we are different
Other resources exist.
None do all of this.
We built on top of the same trusted sources; we did not replace them. We connected them, translated them, and made them findable.
Scroll to compare
We stand on the shoulders of ClinicalTrials.gov, Orphanet, NORD, GARD, and Open Targets. These are essential resources. RareTrial connects them.
Data you can trust
Free data, open licences,
no hidden agenda.
Where the data comes from
- ▸ClinicalTrials.gov: US National Library of Medicine. Public domain. The world's largest clinical trial registry.
- ▸Open Targets Platform: Wellcome Sanger / EMBL-EBI. CC BY 4.0. The scientific standard for drug-target evidence.
- ▸Orphanet / Orphadata: INSERM / European Commission. CC BY 4.0. The definitive rare disease classification system.
What we do with it
- ▸We do not sell data, advertise treatments, or accept payment to feature any drug, trial, or organisation.
- ▸We do not scrape, fabricate, or modify clinical information. What you read is what the source says.
- ▸RareTrial is not a medical service. We are an information bridge. Always verify with your clinical team.
- ▸The platform is and will remain free to every patient, carer, and clinician in the world.
A rare disease diagnosis is not the end of the search.
It is the beginning
of finding what is possible.
RareTrial is operated by Shika Group Ltd. Free to access. Not a medical service.